Summary of Published Health Economic Studies of Cetuximab as Third Line Treatment for Patients with Metastatic Colorectal Cancer [Internet].

We have summarised published Norwegian and international studies of the cost-effectiveness of cetuximab in combination with irinotecan as third line treatment for patients with metastatic colorectal cancer. The present alternative to such treatment is supportive care. The estimated number of patients with metastatic colorectal cancer eligible for treatment with cetuximab + irinotecan as third line therapy is 70.

http://ift.tt/2DnBkLg